FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients

Cancer Genetics and Cytogenetics

Volumn 183, Issue 1, 2008, Pages 35-40

  Paiva, Márcia ^a   Marques, Herlander ^a   Martins, Ângelo ^a   Ferreira, Paula ^a   Catarino, Raquel ^a   Medeiros, Rui ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FC RECEPTOR IIA; FLUDARABINE; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; RITUXIMAB; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT; FC RECEPTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; DNA DETERMINATION; FEMALE; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT OUTCOME; DRUG RESISTANCE; GENETICS; MIDDLE AGED; MORTALITY; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, IGG; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 43149113005     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.02.001     Document Type: Article

References (33)

1. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
2. Ansell S.M., and Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80 (2005) 1087-1097
3. Traulle C., and Coiffier B.B. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma. Future Oncol 1 (2005) 297-306
4. Kennedy R.C., and Shearer M.H. A role for antibodies in tumor immunity. Int Rev Immunol 22 (2003) 141-172
5. Eisenbeis C.F., Caligiuri M.A., and Byrd J.C. Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?. Clin Cancer Res 9 (2003) 5810-5812
6. Rastetter W., Molina A., and White C.A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55 (2004) 477-503
7. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Ferme C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., and Coffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
8. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
9. Cartron G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
10. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6 (2006) 859-866
11. van Sorge N.M., van der Pol W.L., and van de Winkel J.G. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61 (2003) 189-202
12. Cohen-Solal J.F., Cassard L., Fridman W.H., and Sautes-Fridman C. Fc gamma receptors. Immunol Lett 92 (2004) 199-205
13. Dijstelbloem H.M., van de Winkel J.G., and Kallenberg C.G. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22 (2001) 510-516
14. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., and de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90 (1997) 1109-1114
15. de Haas M. IgG-Fc receptors and the clinical relevance of their polymorphisms. Wien Klin Wochenschr 113 (2001) 825-831
16. Lee W., Lockhart A.C., Kim R.B., and Rothenberg M.L. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10 (2005) 104-111
17. Pinto D., Pereira D., Portela C., da Silva J.L., Lopes C., and Medeiros R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 335 (2005) 1173-1178
18. Medeiros R., Pereira D., Afonso N., Palmeira C., Faleiro C., Afonso-Lopes C., Freitas-Silva M., Vasconcelos A., Costa S., Osório T., and Lopes C. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8 (2003) 156-161
19. Santos A.M., Sousa H., Portela C., Pereira D., Pinto D., Catarino R., Rodrigues C., Araújo A.P., Lopes C., and Medeiros R. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340 (2006) 256-262
20. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947
21. Kim D.H., Jung H.D., Kim J.G., Lee J.J., Yang D.H., Park Y.H., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 108 (2006) 2720-2725
22. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
23. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31 (1971) 1860-1861
24. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329 (1993) 987-994
25. Solal-Celigny P., Roy P., Colombat P., White J., Armitage J.O., Arranz-Saez R., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265
26. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
27. Mullenbach R., Lagoda P.J., and Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet 5 (1989) 391
28. Jiang X.M., Arepally G., Poncz M., and McKenzie S.E. Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Meth 199 (1996) 55-59
29. Coiffier B., Lepage E., and Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell Lymphoma. N Engl J Med 346 (2002) 235-242
30. Mounier N., Briere J., Gisselbrecht C., Emile J.F., Lederlin P., Sebban C., Berger F., Bosly A., Morel P., Tilly H., Bouabdallah R., Reyes F., Gaulard P., and Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 (2003) 4279-4284
31. Anderson D.R., Grillo-Lopez A., Varns C., Chambers K.S., and Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Transact 25 (1997) 705-708
32. Golay J., Zaffaroni L., Vaccari T., Lazzari M., Borleri G.M., Bernasconi S., Tedesco F., Rambaldi A., and Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95 (2000) 3900-3908
33. Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clinics 20 (2006) 585-612